Angiography Consent—Communicating Risk Versus Benefit
Reynolds, G. Armstrong, R. Newcombe, T. Wijohn
Heart Lung and Circulation, July 2023; 32(3)
Abstract
Background and Aim
To produce health health-literate patient resources takes a village! It requires many iterations, opinions and feedback from writers, experts and, most importantly, consumers. This poster focuses on the health literacy input, breaking down medical terminology and complex words, seeking consumer feedback and adding images, to enable wider comprehension whilst developing a resource aimed at patient education prior to the consent process for invasive coronary angiography.
Context
The proportion of adults in Australia and New Zealand with reading at levels one or two is similar, at around 44%, meaning they are likely to struggle to understand sufficient health information to make truly informed choices; further compounded in indigenous people and residents with English as a second language. Our Cardiology team at Te Whatu Ora-Waitemata and from the University of Auckland noted a gap at our hospitals; patients had limited access to cardiology staff in wards outside the Cardiology department and largely had no pre-procedural information prior to arriving at the cath lab and being consented.
Progress
We are developing an accessible resource for people awaiting angiography as in-patients, to be educated concerning the process and risks involved for this procedure from the referral time, to enable informed and meaningful consent. The team researched patient understanding of statistical presentation of risk; this will also be available at this meeting.
The language of consent: do we take or does the patient give?
The language of consent: do we take or does the patient give?
Opinion
Simon M Everett
BMJ Endoscopy, 3 August 2023
Excerpt
… The other thing I hear frequently is how best to ‘take consent’. Let us be clear, we cannot ‘take consent’. The only action that deems consent to be legal is that it is ‘freely given’ and that is the basis on which we should talk to our patients. The patient gives us their consent and we receive it, but we do not take it.
Is this just pointless pedantry? Maybe, but if we are using words that describe the consent process incorrectly, it is likely that we are not allocating the time and space that this discussion requires. If we continue to use incorrect terminology, we will continue in the paternalistic way of thinking. Too often in medical practice consent is seen as a time- consuming barrier to doing the things that we believe to be best for our patients. Yes, it can be time consuming, but the more I avail patients of my time, the more I find they need it…
Informed Consent: A Monthly Review
_________________
August 2023 :: Issue 56
This digest aggregates and distills key content addressing informed consent from a broad spectrum of peer-reviewed journals and grey literature, and from various practice domains and organization types including international agencies, INGOs, governments, academic and research institutions, consortiums and collaborations, foundations, and commercial organizations. We acknowledge that this scope yields an indicative and not an exhaustive digest product.
Informed Consent: A Monthly Review is a service of the Center for Informed Consent Integrity, a program of the GE2P2 Global Foundation. The Foundation is solely responsible for its content. Comments and suggestions should be directed to:
Editor
Paige Fitzsimmons, MA
Associate Director, Center for Informed Consent Integrity
GE2P2 Global Foundation
paige.fitzsimmons@ge2p2global.org
PDF Version: Center for Informed Consent Integrity – A Monthly Review_August 2023
Upcoming Calls For Public Consultation
UPCOMING CALLS FOR PUBLIC CONSULTATION
We will selectively include calls for public consultation from multilateral agencies, governments, INGOs and other sources where there is a clear intersection with consent/assent. This might be obvious from the title of the draft guidance, regulations, etc., but more often, it will be a thematic area or topic – if is not addressed at all. If you would like to explore participation with our working group developing submissions for these calls, please contact us [david.r.curry@ge2p2global.org].
Public Consultation: ICH E6(R3) [GCP] Principles, Annex 1 and Annex 2
The E6(R3) EWG is working on the revision of the E6(R2) Guideline “Good Clinical Practice” (GCP) with a view to addressing the application of GCP principles to the increasingly diverse trial types and data sources being employed to support regulatory and healthcare related decision-making on drugs, and provide flexibility whenever appropriate to facilitate the use of technological innovations in clinical trials. Additional information may also be found in ICH Reflection Paper on “GCP Renovation” on the ICH Reflection Paper page. When complete, E6(R3) will be composed of an overarching principles and objectives document, Annex 1 and Annex 2. E6(R3) Draft Guideline. [See Section 2.8 – Informed Consent of Trial Participants]
Public consultation dates:
ANVISA, Brazil – Deadline for comments by 31 August 2023
EC, Europe – Deadline for comments by 26 September 2023
MHRA, UK – Deadline for comments by 31 August 2023
TFDA, Chinese Taipei – Deadline for comments by 31 August 2023
FDA Announces Additional Steps to Modernize Clinical Trials
https://www.fda.gov/news-events/press-announcements/fda-announces-additional-steps-modernize-clinical-trials
ICH HARMONISED GUIDELINE GOOD CLINICAL PRACTICE (GCP) E6(R3)
June 06, 2023 Comment period: Aug 6 2023
Today, the U.S. Food and Drug Administration is announcing the availability of a draft guidance with updated recommendations for good clinical practices (GCPs) aimed at modernizing the design and conduct of clinical trials, making them more agile without compromising data integrity or participant protections. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation’s (ICH) recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise…
This draft guidance, once finalized, would update the existing guidance titled, E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) (March 2018). The revised draft recommendations are designed to be applicable to a broad range of clinical trials including those with innovative design elements. These elements have the potential to make trials more efficient and less burdensome. Additionally, the modernized GCP recommendations encourage the use of fit-for-purpose innovative digital health technologies (DHTs). DHTs, such as wearable sensors could potentially facilitate more agile data collection and assist with patient recruitment.
Public consultation on WHO guidance for best practices for clinical trials
WHO – 19 July 2023
Call for consultation: Deadline 15 Sep 2023
Draft Guidance PDF: https://cdn.who.int/media/docs/default-source/research-for-health/2023-07_who-guidance-for-best-practices-for-clinical-trials_draft-for-public-consultation.pdf?sfvrsn=7a5c9fa5_3
Overview
In May 2022, the Seventy-fifth World Health Assembly adopted a resolution on Strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination, in which one action requested of the Director-General was to develop WHO guidance on best practices for clinical trials. WHO is launching a public consultation on draft guidance developed in line with this request. We aim to obtain input from all relevant stakeholders, spanning all diseases and health conditions during this consultation, so that these inputs can be taken into account in revision of this draft, following advice from the WHO Technical Advisory Group established to support this process.
Important stakeholder groups for this technical guidance include, (but are not restricted to): public sector researchers, private sector entities engaged in clinical trials, national health authorities or research councils involved in health research, clinical trial registries, research ethics bodies, national or transnational medicinal product regulatory authorities, decision-making bodies making use of evidence such as guidelines developers, and health technology assessment bodies, healthcare practitioners, patient engagement and community engagement entities, and professional associations in disciplines for whom clinical trials of health interventions are relevant. There may also be some relevance to medical journals.
We would like to receive your overall comments on what the draft guidance does well and less well at the moment, as well as comments on the sections of the document and line by line if desired. Please review the request for guidance development in WHA resolution 75.8 before providing comments…
[See Section 2.2.2 – Relevant Consent]
Symposia/Conferences
SYMPOSIA/CONFERENCES
We will selectively include information on symposia and conferences which included papers/panels/ workshops which treat issues, evidence, analysis or debates involving consent/assent. Generally, we will identify specific sessions in such meetings with a link to a recorded version [i.e. You Tube].
UNESCO – International Conference on the Ethics of Neurotechnology
13 July 2023, UNESCO Paris
UNESCO organized an International Conference on the Ethics of Neurotechnology on the theme “Towards an Ethical Framework in the Protection and Promotion of Human Rights and Fundamental Freedoms” at UNESCO Headquarters in Paris, on 13 July 2023.
As one of the most promising technologies of our time, neurotechnology is providing new treatments and improving preventative and therapeutic options for millions of individuals suffering from neurological and mental illness. Neurotechnology is also transforming other aspects of our lives, from student learning and cognition to virtual and augmented reality systems and entertainment. While we celebrate these unprecedented opportunities, we must be vigilant against new challenges arising from the rapid and unregulated development and deployment of this innovative technology, including among others the risks to mental integrity, human dignity, personal identity, autonomy, fairness and equity, and mental privacy.
Engaging all relevant stakeholders, including policymakers, lawmakers, scientists, ethicists, practitioners, and private sector companies, is crucial to gather various views and prepare the ground for shaping the ethical governance of neurotechnology.
Event recording: https://webcast.unesco.org/events/2023-07-neurotech/
Supporting documentation:
Ethical issues of neurotechnology: report, adopted in December 2021
Corporate author : International Bioethics Committee [200]
ISBN : 978-92-3-100551-0 Collation : 93 pages Language : English Year of publication : 2022
Workshop on Ethics of Sharing Individual Level Human Brain Data Collected in Biomedical Research
NIH BRAIN Initiative
July 17 and 18, 2023
Data sharing accelerates scientific progress and maximizes the societal value of research, providing an ethical imperative to share data. The ethical considerations tied to the sharing of human brain data may be different than sharing other kinds of biomedical data. Indeed, sharing human research data may involve potential risks to participants or communities. NIH is committed to promoting responsible data sharing (NOT-OD-21-013). In order to put appropriate safeguards in place to manage potential risks of data sharing, a better understanding of what the risks are of sharing different types of human brain data is critical.
The NIH BRAIN Initiative is at the forefront of data sharing in neuroscience (see NOT-MH-19-010). As such, it also has an opportunity to carefully consider the ethical challenges involved, especially with the input of the BRAIN Neuroethics Working Group (NEWG), a group of experts in neuroethics and neuroscience.
The workshop aims to explore meaningful ways to categorize human brain data by potential risks of data sharing. Furthermore, any resulting differences in how to treat the data will be considered.
Spotlight Articles
SPOTLIGHT ARTICLES
In the May 2023 edition of Informed Consent: A Monthly Review we included the BMJ article by Anna Smajdor just below. Smajdor argues for using assent as a way of recognizing those who are unable to provide consent, which she states “…is a way of responding to [the] moral need for recognition, which exists independently of cognitive capacity…”
Of course, laws, regulation, etc. addressing assent vary widely across the globe [where they exist at all] but typically reference “capacity” in some way. Additionally, such laws/regs often include “maturity” and the assessment of capacity, sometimes identifying who has authority to “determine” capacity.
With regard to assent involving children, Smajdor reminds us “..The importance of respecting children’s views, regardless of legal capacity to give consent, has also been codified elsewhere: Article 12 of the United Nations Convention on the Rights of the Child states that ‘States Parties shall assure to the child who is capable of forming his or her own views the right to express those views freely in all matters affecting the child, the views of the child being given due weight in accordance with the age and maturity of the child.’17
There have been a number of responses in the literature to the Smajdor article which we present below. We conclude this section with a follow-up from Smajdor responding to the various commentaries. We would be interested in hearing your perspective, as we may revisit this in a future edition!
Reification and assent in research involving those who lack capacity
Anna Smajdor
BMJ, 26 December 2022
Open Access
Abstract
In applied ethics, and in medical treatment and research, the question of how we should treat others is a central problem. In this paper, I address the ethical role of assent in research involving human beings who lack capacity. I start by thinking about why consent is ethically important, and consider what happens when consent is not possible. Drawing on the work of the German philosopher Honneth, I discuss the concept of reification—a phenomenon that manifests itself when we fail to observe or respond to our fellow humans’ need for recognition. I suggest that assent is a way of responding to this moral need for recognition, which exists independently of cognitive capacity. I will look at the circumstances in which consent cannot be obtained from human beings, and ask whether some of the same ethically important considerations that underpin the need for consent might be achieved through seeking assent. I discuss the ways in which this might be beneficial for researchers, for prospective research participants and for society at large.
Conclusion
In this paper, I have shown that the efforts we make to ‘protect’ those who lack capacity in the context of medical research may ultimately contribute to a world in which such people are systematically disadvantaged. The moral frameworks that govern medical research are geared towards ‘reasonable’ people who can give informed consent. Yet, as I have indicated, this is an idealistic vision which bears little resemblance to the day-to-day reality of medical treatment and research. Informed consent has become a perfunctory exercise which neither serves to respect autonomy, nor to dispel the misconceptions that many research participants have. We are too hasty to regard informed consent as the cornerstone of ethical research, and too rigid in our understanding of the relationship between consent, rationality and autonomy. It is undeniable that medical research can be harmful to participants, and that biomedical researchers can be dangerous people. However, if we place effective limits on the powers of researchers to inflict harm on research participants, it is not clear that we have additional grounds to think that those who lack capacity should be excluded from research.
Paying attention to people’s preferences and interests offers a way of engaging with those who lack capacity. Gaining assent, and respecting dissent in these groups offers greater scope for researchers to recognise their needs. In contrast, to exclude such groups by default is to define them solely in terms of their incapacity, and risks entrenching a reifying disposition that creates boundaries between us and them. While there are many legal and ethical complexities involved in medical research with those who lack capacity, there are ways in which the current status quo could be improved. The recognition/reification dichotomy offers a way of conceptualising the relationships that we can have with those who cannot give informed consent.
Call for moral recognition as part of paediatric assent
Commentary
Jared Smith, Jennifer Blumenthal-Barby
Journal of Medical Ethics, 22 June 2023
Excerpt
In ‘Reification and Assent in Research Involving Those Who Lack Capacity’, Smajdor argues that adults with impaired capacity to grant informed consent (AWIC) are often excluded from participating in biomedical research because they cannot provide informed consent, leading to decreased chances AWIC will benefit from such research. Smajdor uses Honneth’s concept of reification to propose that securing assent (rather than consent) in cases involving AWIC offers patients moral recognition that is not tied to their capacities. Assent provides this recognition by including the patient in a shared moral sphere, highlighting her agency and worth without reducing her to her incapacity or a thing-to-be-managed. Assent also avoids grounding in, or a reliance on, the future development of autonomy (pp.5–6).
Our recent research on patient and caregiver perspectives of potential paediatric deep brain stimulation (pDBS) for refractory obsessive–compulsive disorder (OCD) and dystonia demonstrates that paediatric neurosurgery patients desire the kind of recognition Smajdor associates with assent, and their caregivers largely agree.[2,3] Since (generally) paediatric patients in the USA are unable to grant informed consent, their caregivers must provide it instead. This raises the question of how to properly integrate paediatric patients into the DBS decision-making process.
Assent to research by the formerly competent: necessary and sufficient?
Commentary
Hojjat Soofi
Journal of Medical Ethics, 22 June 2023
Excerpt
Anna Smajdor offers a fresh perspective on why assent is morally required in research practices involving people who (are considered to) lack the capacity to consent. Smajdor holds that seeking (and documenting) assent can be a mechanism to recognise those who (are considered to) lack the capacity to consent as participants ‘in our moral sphere’. Smajdor suggests that this approach can function as a counter to the ‘reifying’ attitudes (often) taken towards people who (are judged to) lack the capacity to consent. Smajdor’s approach also offers novel resources to overcome what Giles Birchley characterise as ‘the problems of the binary approach to incapacity’.
Particularly in the context of dementia research, Smajdor’s proposal can be seen as a promising direction for going beyond the conventional (primarily) ‘protective’ approach taken by research ethics committees. The conventional approach asks researchers to obtain autonomous authorisation from research participants and (at times, implicitly) relies on the assumption that the ability to give consent is the only autonomy-related ability or, in other words, the assumption that the inability to give consent indicates vulnerability due to non-autonomy/non-agency. But this assumption, as Smajdor notes, seems problematic. The ability to assent (or dissent) is also an autonomy-related ability.
Assent: going beyond acknowledgement for fair inclusion
Commentary
Alice Cavolo, Chris Gastmans
Journal of Medical Ethics, 22 June 2023
Excerpt
In her article Reification and assent in research involving those who lack capacity, Anna Smajdor shows how excluding adults with impairments of capacity (AWICs) to protect them from the risks of medical research has the paradoxical effect of harming them by reifying them.1 While the medical risks of excluding vulnerable populations in general from medical research are well known, the main risk being the creation of therapeutic orphans, the risk of reifying these populations is less discussed. Hence, we commend Smajdor for introducing an essential nuance in the debate on inclusion of AWICs in medical research. We also agree with her on the importance of acquiring assent from those who cannot legally consent rather than automatically excluding them from research, as we already do in paediatric research. However, we believe that she fails to acknowledge some practical challenges already observed in paediatric research that hinder the retrieval of assent from AWICs and, consequently, their inclusion in medical research. In this commentary, we will first introduce the main challenge to using assent to include AWICs in research, that is, the fact that individuals might oscillate within the capacity spectrum. We will then provide other examples of practical obstacles to the inclusion of AWICs…
Vulnerable person investigation plan (VIP) to optimise inclusion in clinical trials
Commentary
Ilana C Raburn, Eline M Bunnik, Antonia J Cronin
Journal of Medical Ethics, 22 June 2023
Excerpt
Smajdor addresses the problem of inferior clinical outcomes among adults with impairments of capacity to give informed consent (AWIC). She notes that AWIC are generally excluded from clinical trials to protect them against harms and avoid exploitation and claims there is a causal link between involvement in clinical trials and favourable outcomes. She argues, given this link, that we should increase AWIC representation in clinical trials and can justifiably do so by recognising the capacity of AWIC to assent.
AWIC form a diverse group, with multiple aetiologias, including, for example, Down syndrome, traumatic brain injury and dementia. In some cases, the inability to consent may fluctuate so that the same person could be AWIC only at certain times. Yet despite these differences, the group has a shared unmet need. We agree with Smajdor that AWIC outcomes should be improved, but question whether simply increasing representation in clinical trials is sufficient to achieve this…
What should recognition entail? Responding to the reification of autonomy and vulnerability in medical research
Commentary
Jonathan Lewis, Soren Holm
Journal of Medical Ethics, 22 June 2023
Excerpt
Smajdor claims that ‘recognition’ is the solution to the ‘reifying attitude’ that results from ‘the urge to protect “vulnerable” people through exclusion from research’. Specifically, for Smajdor, an assent-based framework—as a means of recognising and respecting the autonomy of vulnerable individuals who would otherwise be excluded from biomedical research—provides such recognition.
If the sole reason for the reification of vulnerable individuals in research contexts is a need to protect them due to their inability to fulfil standards for informed consent, then recognition in the form of assent would, in principle, provide a solution to the reification issue. The central claim of this commentary, however, is that what has been reified are the concepts of autonomy and vulnerability themselves. On that basis, overcoming such reification demands a deeper consideration of the forms that recognition should take if we are to enable vulnerable individuals to make autonomy claims concerning research participation.
Smajdor appeals to Honneth’s account of reification, for which one of starting points is Adorno’s characterisation of reification as ‘identity-thinking’. For Adorno, what identity thinking entails is that concepts ‘are no longer measured against what they contain, and what they contain is no longer measured against concepts; instead, concepts are taken in isolation’. In short, individuals are reduced to concepts such that their ‘particularity’, ‘heterogeneity’ and ‘individuality’ are ignored…
Understanding the autonomy of adults with impaired capacity through dialogue
Commentary
Alistair Wardrope, Simon Bell, Daniel Blackburn, Jon Dickson, Markus Reuber, Traci Walker
Journal of Medical Ethics, 22 June 2023
Excerpt
Smajdor invites welcome interrogation of the distance between our philosophical justifications of how we engage people in decisions about healthcare or research, and the ways we do so.1 She notes the implicit elision made between autonomy and informed consent, and argues the latter alone cannot secure the former, proposing a more flexible approach.
As researchers working with people with dementia (PwD), we share Smajdor’s reservations. We argue that an autonomy worthy of respect requires not just decision-making capacity, but also authenticity; the ability to deter mine for oneself what is good for oneself.2 Furthermore, our relationships support or undermine both capacity and authenticity, and autonomous expression manifests throughout evolving relationships. This invites us to view respect differently—as an ongoing conversation with another person, capable of holding values that may move us. In Smajdor’s terminology, it requires that we recognise them. We describe how we operationalise this in our research…
Assent and reification: a response to the commentators
Commentary
Anna Smajdor
Journal of Medical Ethics, 22 June 2023
Excerpt
My paper on assent and reification in research involving adults with impairments of capacity and/or communication (AWIC) drew many thoughtful and insightful responses. I am grateful to all who submitted commentaries.
Most agreed in principle that AWIC could be better represented in medical research. However, several commentators felt that further clarification was needed in terms of what assent is and how it should be obtained and operationalised. I fully agree that if increased representation of AWIC is to come about through an assent-based approach, further clarificatory work is needed, and am glad to think my paper may function as a stimulus for this.
Some commentators worry that an assent-based approach will impose heavy demands on researchers and entail higher costs. I acknowledge this, but would argue that if better inclusion of AWIC is a worthwhile goal, we should be willing to accept some costs. The move from an exclusionary to an inclusive approach will become less demanding once it is accepted as the default. And as I argue in my paper, we have resources on which to draw, including materials designed to facilitate comprehension and communication with AWIC that have been developed in other spheres, as well as existing protocols and structures that facilitate…
Struggling with unnecessary suffering-Registered nurses’ experiences of delayed decisions on treatment without consent in forensic psychiatric inpatient care
Struggling with unnecessary suffering-Registered nurses’ experiences of delayed decisions on treatment without consent in forensic psychiatric inpatient care
Antonsson H, Dahliavy L, Mouline H, Molin J
International Journal of Mental Health Nursing, 17 July 2023
Abstract
Chemical restraints are used in forensic psychiatric inpatient care, however with caution as it can feel like an assault against patients’ integrity. When waiting for decisions on treatment without consent, nursing staff are expected to care for patients with severe mental ill-health without the use of medical treatment, often with a feeling of already having tried all other available means. Knowledge about how registered nurses experience such situations is sparse but could contribute to the development of both teamwork and nursing approaches that could mean reduced suffering for patients. The aim of this study was to describe registered nurses’ experiences of delayed decisions on treatment without consent in forensic psychiatric inpatient care. Eleven semi-structured interviews were conducted with registered nurses working in forensic psychiatric units in Sweden. Data were analysed through qualitative content analysis. The result showed that experiences of treatment without consent were about striving to protect patients from harm, striving for collaboration during difficult circumstances and striving to do good. This was interpreted as a struggle with unnecessary suffering. For registered nurses to be able to handle such challenging situations and relieve suffering for patients, experience and master-level education in mental health nursing are highlighted. Another aspect that is highlighted is the importance of having consultants familiar with the circumstances at the unit. A method for joint reflection is suggested, to promote an open-minded work culture with a well-functioning decision-making process and ensure that both consultants and nursing staff have support.
A randomized comparison of two-stage versus traditional one-stage consent for a low-stakes randomized trial
A randomized comparison of two-stage versus traditional one-stage consent for a low-stakes randomized trial
Research Article
Andrew J Vickers, Emily A Vertosick, Mia Austria, Christopher D Gaffney, Sigrid V Carlsson, Scott YH Kim, Behfar Ehdaie
Clinical Trials, 4 July 2023
Abstract
Background/Aims
It has been proposed that informed consent for randomized trials should be split into two stages, with the purported advantage of decreased information overload and patient anxiety. We compared patient understanding, anxiety and decisional quality between two-stage and traditional one-stage consent.
Methods
We approached patients at an academic cancer center for a low-stakes trial of a mind–body intervention for procedural distress during prostate biopsy. Patients were randomized to hear about the trial by either one- or two-stage consent (n = 66 vs n = 59). Patient-reported outcomes included Quality of Informed Consent (0–100); general and consent-specific anxiety and decisional conflict, burden, and regret.
Results
Quality of Informed Consent scores were non-significantly superior for two-stage consent, by 0.9 points (95% confidence interval = −2.3, 4.2, p = 0.6) for objective and 1.1 points (95% CI = −4.8, 7.0, p = 0.7) for subjective understanding. Differences between groups for anxiety and decisional outcomes were similarly small. In a post hoc analysis, consent-related anxiety was lower among two-stage control patients, likely because scores were measured close to the time of biopsy in the two-stage patients receiving the experimental intervention.
Conclusion
Two-stage consent maintains patient understanding of randomized trials, with some evidence of lowered patient anxiety. Further research is warranted on two-stage consent in higher-stakes settings.
Biobanking and consenting to research: a qualitative thematic analysis of young people’s perspectives in the North East of England
Biobanking and consenting to research: a qualitative thematic analysis of young people’s perspectives in the North East of England
Research
Fabian J. S. van der Velden, Emma Lim, Lily Gills, Jasmin Broadey, Louise Hayes, Eve Roberts, Jack Courtney, Joanne Ball, Jethro Herberg, Rachel Galassini, Marieke Emonts
BMC Medical Ethics, 5 July 2023; 24(47)
Open Access
Abstract
Background
Biobanking biospecimens and consent are common practice in paediatric research. We need to explore children and young people’s (CYP) knowledge and perspectives around the use of and consent to biobanking. This will ensure meaningful informed consent can be obtained and improve current consent procedures.
Methods
We designed a survey, in co-production with CYP, collecting demographic data, views on biobanking, and consent using three scenarios: 1) prospective consent, 2) deferred consent, and 3) reconsent and assent at age of capacity. The survey was disseminated via the Young Person’s Advisory Group North England (YPAGne) and participating CYP’s secondary schools. Data were analysed using a qualitative thematic approach by three independent reviewers (including CYP) to identify common themes. Data triangulation occurred independently by a fourth reviewer.
Results
One hundred two CYP completed the survey. Most were between 16–18 years (63.7%, N = 65) and female (66.7%, N = 68). 72.3% had no prior knowledge of biobanking (N = 73). Acceptability of prospective consent for biobanking was high (91.2%, N = 93) with common themes: ‘altruism’, ‘potential benefits outweigh individual risk’, ‘frugality’, and ‘(in)convenience’. Deferred consent was also deemed acceptable in the large majority (84.3%, N = 86), with common themes: ‘altruism’, ‘body integrity’ and ‘sample frugality’. 76.5% preferred to reconsent when cognitively mature enough to give assent (N = 78), even if parental consent was previously in place. 79.2% wanted to be informed if their biobanked biospecimen is reused (N = 80).
Conclusion
Prospective and deferred consent acceptability for biobanking is high among CYP in the UK. Altruism, frugality, body integrity, and privacy are the most important themes. Clear communication and justification are paramount to obtain consent. Any CYP with capacity should be part of the consenting procedure, if possible.
No need for options for choice for unsolicited findings in informed consent for clinical genetic testing
No need for options for choice for unsolicited findings in informed consent for clinical genetic testing
Comment
Eline M. Bunnik
European Journal of Human Genetics, 13 July 2023
Open Access
Excerpt
As demand for clinical genetic testing services is rising rapidly, there is a need for approaches to pre-test counselling and informed consent that are equally effective but less time-consuming. In time-constrained settings, physicians may need to limit themselves to conveying key information to enable patients to make informed decisions about genetic testing. However, there is currently a lack of guidance on what constitutes key information about clinical genetic testing. In this issue, Hallquist and colleagues present a list of ‘core concepts’ that are deemed minimally necessary to discuss with patients prior to genetic testing, which was developed by the Clinical Genome Resource (ClinGen) Consent and Disclosure Recommendations (CADRe) Workgroup. They report the results of a survey of US-based medical geneticists and genetic counsellors, which validate the CADRe list of core concepts as a model for targeted pre-test discussions. The model can be used as a basis for the development and/or revision of (inter)national guidelines for pre-test counselling and informed consent for clinical genetic testing…
Editor’s note: The article in reference by Hallquist et al. can be found here.